Open AccessSynovial fibroblast‐targeting liposomes encapsulating an NF ‐κB‐blocking peptide ameliorates zymosan‐induced synovial inflammation
Author(s) -
You Changcheng,
Zu Jianing,
Liu Xiaoqi,
Kong Pengyu,
Song Chengchao,
Wei Rongzhi,
Zhou Changlong,
Wang Yufu,
Yan Jinglong
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13549
Subject(s) - zymosan , inflammation , arthritis , rheumatoid arthritis , cytokine , chemistry , in vivo , pharmacology , immunology , synovial fluid , nf κb , in vitro , medicine , biology , pathology , biochemistry , osteoarthritis , alternative medicine , microbiology and biotechnology
Synovial fibroblasts ( SF s) play a crucial role in the inflammatory process of rheumatoid arthritis ( RA ). The highly activated NF ‐κB signal in SF s is responsible for most of the synovial inflammation associated with this disease. In this study, we have developed an SF ‐targeting liposomal system that encapsulates the NF ‐κB‐blocking peptide ( NBD peptide) HAP ‐lipo/ NBD . HAP ‐lipo/ NBD s demonstrated efficient SF ‐specific targeting in vitro and in vivo. Our study also showed a significant inhibitory effect of HAP ‐lipo/ NBD on NF ‐κB activation, inflammatory cytokine release and SF migration capability after zymosan stimulation. Furthermore, the systemic administration of HAP ‐lipo/ NBD s significantly inhibited synovial inflammation and improved the pathological scores of arthritis induced by zymosan. Thus, these results suggest that an SF ‐targeting NF ‐κB‐blocking strategy is a potential approach for the development of alternative, targeted anti‐ RA therapies.